http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis (EXEL) Announces Departure of Lance Willsey from Board
-
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
-
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
-
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
-
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
-
Exelixis (EXEL) Advances Board Refreshment Plan
-
Exelixis Advances Board Refreshment Plan
-
Exelixis Reiterates Commitment to Shareholder Value Creation
-
Exelixis (EXEL) Announces $550 Million Share Repurchase Program
-
Exelixis Announces $550 Million Share Repurchase Program
-
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
-
Exelixis (EXEL) Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab
-
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
-
Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
-
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
-
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
-
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
-
Exelixis (EXEL) Issues Update on Patent Litigation with MSN Laboratories
-
Exelixis Announces Update on Patent Litigation with MSN Laboratories
-
Exelixis (EXEL) Reports Prelim Q4 Revenue of $375M, Issues 2023 Guidance and Update
-
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
-
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
-
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
-
Exelixis (EXEL) announces CONTACT-01 study did not meet its primary endpoint
-
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunothera
-
Exelixis (EXEL) Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
-
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
-
Latest Updates of 12 Viva's Portfolio Companies
-
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
-
Exelixis (EXEL) and Catalent (CTLT) Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
-
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
-
Exelixis (EXEL) and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805
-
Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12
-
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
-
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
-
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
Exelixis (EXEL) Reports Promising Initial Dose-Escalation Results from Phase 1 JEWEL-101 Trial of XB002
-
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
-
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
-
Exelixis (EXEL) Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY)
-
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STE
-
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ES
-
Exelixis (EXEL) Announces More Detailed Results of Phase 3 COSMIC-313 Trial in Advanced Kidney Cancer at ESMO
-
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
-
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
